Haoxi Health Technology Plunges 40% as 1-for-128 Reverse Split Looms

Haoxi Health Technology Limited (NASDAQ: HAO) tumbled 40.4% intraday on May 19, 2026, as the Beijing-based digital marketing firm executed a 1-for-128 reverse stock split. The Chinese advertising platform, which serves healthcare clients through platforms like Douyin and WeChat, saw trading volume explode to 809 million shares—over 40 times its daily average. The stock now trades at $0.0134 USD, down from $0.0225 at the previous close. This dramatic move reflects ongoing pressure on HAO stock as the company battles operational challenges and market skepticism.

Reverse Split Execution and Market Impact

The reverse split took effect at the opening of The Nasdaq Capital Market on Thursday, consolidating every 128 shares into one. Haoxi announced the 1-for-128 reverse split to maintain compliance with exchange listing standards. Class A ordinary shares continue trading under the HAO symbol.

The split compressed share count dramatically but failed to stabilize the stock. Trading volume reached unprecedented levels as investors repositioned holdings. The company’s market cap sits at just $133,554 USD, reflecting severe valuation compression. HAO stock trades well below its 50-day average of $0.9556 and 200-day average of $1.1199, signaling sustained downward pressure.

Financial Deterioration and Profitability Crisis

Haoxi faces mounting operational headwinds reflected in negative profitability metrics. The company posted a net loss of $0.62 per share trailing twelve months, with operating margins at -17.7%. Revenue per share reached $9.51, but the firm burned cash with negative operating cash flow of $0.75 per share.

Meyka AI rates HAO with a grade of B-, reflecting mixed fundamentals. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s return on equity stands at -16.6%, indicating shareholder value destruction. These grades are not guaranteed and we are not financial advisors. Track HAO on Meyka for real-time updates on this volatile position.

Technical Breakdown and Oversold Signals

Technical indicators flash extreme distress across multiple measures. The Relative Strength Index (RSI) sits at 13.72, deep in oversold territory below 30. The Awesome Oscillator reads -0.79, and Williams %R plunged to -99.80, suggesting capitulation selling.

The stock trades below both its 50-day and 200-day moving averages, confirming a severe downtrend. The Average True Range (ATR) of 0.12 reflects compressed volatility despite massive price swings. Money Flow Index (MFI) at 0.11 indicates institutional selling pressure. These technical signals suggest HAO stock has lost investor confidence entirely.

Haoxi Health Technology Limited Price Forecast

Meyka AI’s forecast model projects HAO stock could reach $14.47 USD within one year, implying +107,700% upside from current levels. The three-year forecast stands at $50.50, and the five-year target reaches $85.95 USD. These projections assume operational recovery and market stabilization.

However, current fundamentals offer little support for such gains. The company must demonstrate revenue growth, restore profitability, and rebuild investor confidence. The reverse split alone cannot reverse the underlying business deterioration. Investors should monitor quarterly earnings and cash burn rates closely before considering entry.

Final Thoughts

Haoxi Health Technology’s 40% intraday crash and reverse split execution mark a critical inflection point for the struggling Chinese digital marketer. With HAO stock trading near penny-stock levels, negative earnings, and technical indicators flashing distress, the company faces an uphill battle to restore shareholder value. The reverse split buys time for compliance but does not address core operational challenges. Investors should await concrete evidence of business stabilization and profitability before reconsidering HAO stock positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.